Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues
- Sponsor
- Cairo University
- Study ID
- NCT07599241
- Status
- Recruiting
Conditions
- Non-Alcoholic Fatty Liver Disease
- Primary Open Angle Glaucoma
- Subclinical hypothyroïdism
Eligibility Criteria
- Sex
- FEMALE
- Age
- 65 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- physical activity — BEHAVIORALhypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month
- usual care — OTHERhypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine only
Study Details
additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated
Key Dates
- First listed
- May 20, 2026
- Start date
- Mar 15, 2026
- Status verified
- May 2026
- Primary completion
- Dec 15, 2026
- Completion
- Dec 15, 2026
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: group number 1hypthyroidism elder females (n=20) with glaucoma and fatty liver issues recive their levothyroxine and physical activity program on treadmill thrice weekly for 6 month
- Active Comparator: group number 2hypthyroidism elder females (n=20) with glaucoma and fatty liver issues will recive their levothyroxine only
Primary Outcome Measure
intraocular pressure [ Time Frame: 6 months ]
Central Contacts
- Ali MA Ismail, lecturer01005154209
- fatma M Ali01031321109
Related Studies
- Diagnostic Innovations in Glaucoma StudyRecruiting · University of California, San Diego · La Jolla, California
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver DiseasePHASE2 · Not Yet Recruiting · Justin Ryder · Chicago, Illinois
- Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)PHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- The Olmsted NAFLD Epidemiology Study (TONES)Recruiting · Mayo Clinic · Rochester, Minnesota